Masuoka K. Lorianne - Jan 22, 2024 Form 4 Insider Report for DiaMedica Therapeutics Inc. (DMAC)

Role
Chief Medical Officer
Signature
/s/ Amy E. Culbert, attorney-in-fact
Stock symbol
DMAC
Transactions as of
Jan 22, 2024
Transactions value $
$0
Form type
4
Date filed
1/23/2024, 04:23 PM
Previous filing
Mar 3, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding DMAC Voting Common Shares, no par value per share 0 Jan 22, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DMAC Stock option (right to buy) Award $0 +285K $0.00 285K Jan 22, 2024 Common Shares 285K $2.79 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Vests with respect to 25% of the underlying common shares on January 22, 2025 and with respect to the remaining 75% of the underlying common shares vesting quarterly over the following three years commencing on April 1, 2025.